Response to "Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality"

Int J Cardiol. 2015 Jun 15:189:247-8. doi: 10.1016/j.ijcard.2015.04.125. Epub 2015 Apr 16.

Authors

Daniele Pastori¹, Alessio Farcomeni², Tommaso Bucci³, Roberto Cangemi³, Paolo Ciacci³, Tommasa Vicario³, Francesco Violi³, Pasquale Pignatelli³

Affiliations

¹ I Clinica Medica, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinico of Rome, Italy. Electronic address: daniele.pastori@uniroma1.it.
² Department of Public Health and Infectious Diseases, Statistics Section, Sapienza University of Rome, Italy.
³ I Clinica Medica, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Umberto I Policlinico of Rome, Italy.

PMID: 25897918
DOI: 10.1016/j.ijcard.2015.04.125

No abstract available

Keywords: Anticoagulation; Atrial fibrillation; Digoxin; Heart failure; Mortality; Time in therapeutic range.

Publication types

Letter
Comment

MeSH terms

Anticoagulants / therapeutic use*
Atrial Fibrillation / drug therapy*
Digoxin / adverse effects*
Female
Heart Failure / mortality*
Humans
Male
Risk Assessment*
Stroke / mortality*

Substances

Anticoagulants
Digoxin